Advent Of Omicron: An Attempt to Decode the Third Wave Covid Variant
DOI:
https://doi.org/10.14738/jbemi.93.12213Keywords:
Booster dose, Omicron, SARS‐CoV‐2., Omicron, Variants of concern, VaccinesAbstract
Currently, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has spread worldwide as an Omicron (B.1.1.529) variant, after alpha, beta, gamma, Delta. World Health Organization (WHO) has identified the Omicron variant as a variant of concern due to its heavily mutated nature. Phylogenetically, this variant with more than 50 mutations is very different from other variants. With an average doubling time of two days, the Omicron variant spreads rapidly. However, it has been milder than the Delta. Although previous infection and vaccination do not protect against infection with Omicron, they do appear to protect against hospitalization and severe disease. It is likely that Omicron will have enormous indirect effects, such as lockdowns, restrictions, travel bans, economic losses, infections of healthcare workers, and an overwhelming of healthcare facilities. However, as with previous variants, Omicron's direct effects are expected to be mild. Nevertheless, the indirect effects on mental, physical, and social health may be considerable. It is recommended to for all the people to follow the COVID-19 behaviours. In this review, we focused on the emergence, severity, genomics, effectiveness of vaccines, and treatment and management strategy against the Omicron variant, which will be helpful for further investigation of a new variant of SARS‐CoV‐2.
References
Enhancing response to Omicron SARS-CoV-2 variant. Available from: https://www.who.int/publications/m/item/enhancing-readiness-for-Omicron-(b.1.1.529)-technical-briefand-priority-actions-for-member-states. [Access on 01 February 2022].
European Centre for Disease Prevention and Control. Implications of the emergence and spread of the SARSCoV-2 B.1.1. Vol. 529 variant of concern (Omicron), for the EU/EEA. Stockholm: European Center for Disease Prevention and Control; Nov 26, 2021.
Viana R, Moyo S, Amoako DG, Tegally H, Scheepers C, Althaus CL, Anyaneji UJ, Bester PA, Boni MF et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature. 2022.
Choi B, Choudhary MC, Regan J, Sparks JA, Padera RF, Qiu X, Solomon IH, Kuo HH, Boucau J, Bowman K, et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised Host. N Engl J Med.
Martin DP, Lytras S, Lucaci AG, Maier W, Grüning B, Shank SD, Weaver S, MacLean OA, Orton RJ, Lemey P, Boni MF et al. Selection analysis identifies unusual clustered mutational changes in Omicron lineage BA.1 that likely impact Spike function. bioRxiv. 2022.
Kannan S, Shaik Syed Ali P, Sheeza A. Evolving biothreat of variant SARS-CoV-2 - molecular properties, virulence and epidemiology. Eur Rev Med Pharmacol Sci. 2021;25(12):4405-12. 71
Kannan S, Shaik Syed Ali P, Sheeza A. Omicron (B.1.1.529) - variant of concern - molecular profile and epidemiology: a mini review. Eur Rev Med Pharmacol Sci. 2021 Dec;25(24):8019-22.
Christie B. Covid-19: early studies give hope Omicron is milder than other variants. British Medical Journal Publishing Group; 2021.
Ranjan R. Omicron impact in India: an early analysis of the ongoing COVID-19 third wave. medRxiv. 2022 Jan 1.
Indias Omicron experience will be same as South Africa, less severe perhaps. Available from: https://science.thewire.in/health/india-Omicron-variant-experience-less-severe-south-africa/. [Access on 01 February 2022].
Singhal T. The emergence of Omicron: challenging times are here again! Indian J Pediatr. 2022:1-7 [advance online publication].
Omicron variant mutating but disease severity mild: Delhi hospital study. Available from: https://www.ndtv.com/india-news/Omicron-variant-mutating-but-disease-severity-mild-delhi-hospitalstudy-2702861[Access on 01 February 2022].
Bansal K, Kumar S. Mutational cascade of SARS-CoV-2 leading to evolution and emergence of Omicron variant. bioRxiv. 2021;2021:2012(2006):471389.
Shu Y, McCauley J. GISAID: global initiative on sharing all influenza data–from vision to reality. Euro Surveill. 2017;22(13):30494.
Hoffmann M, Krüger N, Schulz S, et al. The Omicron variant is highly resistant against antibody-mediated neutralization – implications for control of the COVID-19 pandemic. Cell. Published online December 24, 2021.
Kandeel M, Mohamed MEM, Abd El-Lateef HM, Venugopala KN, El-Beltagi HS. Omicron variant genome evolution and phylogenetics. J Med Virol. 2021 Dec 10. doi: 10.1002/jmv.27515 [Epub ahead of print].
Qin S, Cui Mengnan, Sun S, Zhou J, Du Z, Cui Y, Fan H. Genome characterization and potential risk assessment of the novel SARS-CoV-2 variant Omicron (B.1.1.529). Zoonoses;1(1).
He X, Hong W, Pan X, Lu G, Wei X. SARS-CoV-2 Omicron variant: characteristics and prevention. Med. 2021;2(4):838-45 [advance online publication
Araf Y, Akter F, Tang YD, Fatemi R, Parvez MSA, Zheng C, Hossain MG. Omicron variant of SARS-CoV-2: genomics, transmissibility, and responses to current COVID-19 vaccines. J Med Virol. 2022. doi: 10.1002/jmv.27588 [advance online publication]. https://doi.org/10.1002/jmv.27588.
Available from: https://www.infectioncontroltoday.com/view/flu-or-Omicron-diagnosis-must-be-donequickly.
Mohapatra RK, Sarangi AK, Kandi V, Azam M, Tiwari R, Dhama K. Omicron (B.1.1.529 variant of SARS-CoV-2); an emerging threat: current global scenario. J Med Virol. 2021 Dec 29. doi: 10.1002/jmv.27561 [Epub ahead of print].
Saxena SK, Kumar S, Ansari S, Paweska JT, Maurya VK, Tripathi AK, Abdel-Moneim AS. Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective. J Med Virol. 2021 Dec 14. doi: 10.1002/jmv.27524 [Epub ahead of print].
COVID-19 weekly epidemiological update. Edition 77, Available: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---1-february-2022.
Dejnirattisai W, Shaw RH, Supasa P, Liu C, Stuart AS, Pollard AJ, Liu X, Lambe T, Crook D, Stuart DI, Mongkolsapaya J, Nguyen-Van-Tam JS, Snape MD, Screaton GR, & Com-COV2 study group (2022). Reduced neutralisation of SARS-CoV-2 Omicron B.1.1.529 variant by post-immunisation serum. Lancet;399(10321):234-6.
Ferguson N, Ghani A, Hinsley W, Volz E. Hospitalisation risk for Omicron cases in England. London: Imperial College Press; 2021. Available at: https:// www. imper ial. ac. uk/ media/ imper ial- colle ge/ medic ine/mrc- gida/ 2021- 12- 22- COVID 19- Report- 50. pdf.
Collie S, Champion J, Moultrie H, Bekker LG, Gray G. Effectiveness of BNT162b2 vaccine against Omicron variant in South Africa. N Engl J Med. 2022;386(5):494-6.
Ren SY, Wang WB, Gao RD, Zhou AM. Omicron variant (B.1.1.529) of SARS-CoV-2: mutation, infectivity, transmission, and vaccine resistance. World J Clin Cases. 2022;10(1):1-11.
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W, China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727-33.
She J, Jiang J, Ye L, Hu L, Bai C, Song Y. 2019 novel coronavirus of pneumonia in Wuhan, China: emerging attack and management strategies. Clin Transl Med. 2020;9(1):19
Li L, Huang Q, Wang DC, Ingbar DH, Wang X. Acute lung injury in patients with COVID-19 infection. Clin Transl Med. 2020;10(1):20-7.
Yue L, Zhou J, Zhou Y, Yang X, Xie T, Yang M, Zhao H, Zhao Y, Yang T, Li H, Xiang H, Wang J, Lu S, Liu H, Zhao H, Wei X, Zhang Y, Xie Z. Antibody response elicited by a third boost dose of inactivated SARS-CoV-2 vaccine can neutralize SARS-CoV-2 variants of concern. Emerg Microbes Infect. 2021;10(1):2125-7.
Zhang L, Wang DC, Huang Q, Wang X. Significance of clinical phenomes of patients with COVID-19 infection: a learning from 3795 patients in 80 reports. Clin Transl Med. 2020;10(1):28-35.
Liao Y, Zhang Y, Zhao H, Pu J, Zhao Z, Li D, Fan S, Yu L, Xu X, Wang L, Jiang G, Liu L, Li Q. Intensified antibody response elicited by boost suggests immune memory in individuals administered two doses of SARS-CoV-2 inactivated vaccine. Emerg Microbes Infect. 2021 Dec;10(1):1112-5.
Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K, Kent SJ, Triccas JA, Davenport MP. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021 Jul;27(7):1205-11.
Thye AY-K, Law JW, Tan LT, Pusparajah P, Ser HL, Thurairajasingam S, Letchumanan V, Lee LH. Hooi-Leng ser, Vengadesh Letchumanan, and Learn-Han Lee. Psychological Symptoms in COVID-19 Patients: Insights into Pathophysiology and Risk Factors of Long COVID-19. Biology. 2022;11(1).
Jain A, Jolly TS. Omicron (B.1.1.529) COVID-19 variant: A mental health perspective on lessons learned and future challenges. Prim Care Companion CNS Disord. 2021;23(6).
Ianzito C. Omicron Is Adding Fuel to Mental Health Crisis:anxiety and depression are becoming chronic problems as the pandemic drags on. American Association of Retired Persons; 2022 [cited Feb 1 2022]. Available from: https://www.aarp.org/health/conditions-treatments/info-2022/pandemic-depressionanxiety-increases.html.
Aljazeera. Omicron is sending thousands of children to US hospitals. Vol. 2021; 2021. Aljazeera [cited Feb 2 2022]. Available from: https://www.aljazeera.com/news/2021/12/30/Omicron-is-sending-thousands-ofchildren-to-us-hospitals.
Centers for Disease Control and Prevention. COVID-19 vaccines for children and teens. . Available at: https:// www cdc gov/ coron avirus/. 2019–ncov/ vacci nes/ recom menda tions/ child renteenshtml;2022.
Wang L BN. Volkow ND, Xu R. . Comparison of outcomes from COVID infection in pediatric and adult patients before and after the emergence of Omicron. medRxiv [Preprint] 2022, Kaelber DC. Vol. 2. PB: Davis; 2021:12.30.21268495.
Omicron symptoms seen in kids: everything you need to know. Mint; 2022.
Misra P KS, Guleria R, et al. WHO Unity Serological prevalence study team of AIIMS. Serological prevalence of SARS-CoV-2 antibody among children and young age (between age 2–17 years) group in India: An 73 interim result from a large multi-centric population-based seroepidemiological study.bmedRxiv [Preprint]. 2021.
Engjom H. TvdA, Anna Aabakke, Outi Ayras, Kitty Bloemenkamp, Serena Donati. Severe COVID-19 in pregnancy is almost exclusively limited to unvaccinated women – time for policies to change The Lancet Regional Health. 2022;13.
Ministry of Health family welfare GoI [guidelines] for COVID 19 vaccination of children between 15-18 years and precaution dose to HCWs. FLWs & 60+ population with comorbidities url=https%3A%2F%2Fwwwmohfwgovin%2Fpdf% 2FGuidelinesforCOVID19VaccinationofChildrenbetween15to18yearsandPrecautionDosetoHCWsFLWs%25 2660populationwithcomorbiditiespdf&clen=92242&chunk=true; 2022.
Mandeep Dhaliwal RS, Douglas Webb, Lucie Cluver, Mona Ibrahim, Ludo Bok,Collin Nascimento, Cheng Wang, Aidan Garagic, Lars Jensen. THE WORLD WE WANT: Covid-19 as a long multiwave event: implications for responses to safeguard younger generations. BMJ. 2022;376::e068123.
Parrett M. Important Omicron insights to aid treatment success. PubMed; 2022. Available from: https://pubmedncbinlmnihgov/6192965.
Auwaerter PG. Coronavirus COVID-19 (SARS-CoV-2). Johns Hopkins ABX guide; 2022. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540747/all/Coronavirus_COVID_19__SARS_CoV_2_.
Sharma k. Coronavirus treatment: do you need Molnupiravir, monoclonal antibody cocktail or just symptom-based treatment if you test COVID positive? Here's an explainer. Times of India; 2022.
Klompas M, Karan A. Preventing SARS-CoV-2 transmission in health care settings in the context of the Omicron variant. JAMA. 2022.
Lyngse FP ML, Denwood MJ, et al. SARS-CoV-2 Omicron VOC transmission in Danish households. medRxiv [Preprint]. 2021.
Soriano V, de-Mendoza C, Edagwa B, Treviño A, Barreiro P, Fernandez-Montero JV, Gendelman HE. Oral antivirals for the prevention and treatment of SARS-CoV-2 infection [published online ahead of print, Jan 24 2022]. AIDS Rev. 2022.
Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020;19(3):149-50.
Pruijssers AJ, Denison MR. Nucleoside analogues for the treatment of coronavirus infections. Curr Opin Virol. 2019;35:57-62.
Wang BX, Fish EN. Global virus outbreaks: interferons as 1st responders. Semin Immunol. 2019;43:101300. doi: 10.1016/j.smim.2019.101300.
Tao K, Tzou PL, Nouhin J, Bonilla H, Jagannathan P, Shafer RW. SARS-CoV-2 antiviral therapy. Clin Microbiol Rev. 2021;34(4):e0010921.
Fang FF, Shi PY. Omicron: a drug developer's perspective. Emerg Microbes Infect. 2022;11(1):208-11.
Ferré VM, Peiffer-Smadja N, Visseaux B, Descamps D, Ghosn J, Charpentier C, Omicron S-C. Omicron SARS-CoV-2 variant: what we know and what we don't [published online ahead of print, Dec 10 2021]. Anaesth Crit Care Pain Med. 2021;41(1):100998.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Dr Farah Iram, Aditi Vats, Dr. Anisha Raju, Dr. Betina Chandolia, Mohini Gahlot, Dr. Niveditha Hariharan, Dr. Saurav Deka
This work is licensed under a Creative Commons Attribution 4.0 International License.
